A-Squared Ventures

A-Squared Ventures is the early-stage digital health vehicle of Arkin Capital, and it treats that lineage as a working tool rather than a credential. The fund is explicit that it backs founders building software to attack B2B administrative and operational bottlenecks in the US healthcare system, and it does not pretend its scope reaches further than that.

The thesis is direct. American healthcare is a multi-trillion-dollar mess of administrative friction, and a meaningful portion of that friction is solvable with modern software. A-Squared funds Israeli founders building into that opportunity, with portfolio attention to revenue cycle management, prior authorization, claims and payer-provider workflows, clinical operations software, scheduling, staffing, and the broader category of AI-driven automation across administrative healthcare functions. The firm is genuinely AI-native and tends to favor companies where machine learning is doing real work rather than serving as a coat of paint over a workflow tool.

Checks fall in the one to five million dollar range, with activity across Pre-Seed, Seed, and Series A. The fund is comfortable being the first institutional money in and also comfortable participating in a led round when the syndicate composition makes sense. Geography is structured around Israeli founders selling into US enterprise customers from the start. A-Squared has limited interest in companies that plan to sell first into Israel or Europe, which it views as a misallocation of effort given where the market actually is. The firm expects founders to commit to building US-facing sales motions early, which usually means hiring American GTM talent before most Israeli founders are emotionally ready to.

The team carries the operational orientation of Arkin Capital and does not behave like a passive seed check. Founders should expect substantive engagement on enterprise sales, ICP definition, pricing, and the realities of selling to health systems and payers. The diligence process is grounded in customer reference work and willingness to engage with founders’ assumptions about buyer behavior, often with more rigor than founders expect at Pre-Seed and Seed.

The operating support concentrates where Israeli founders selling US healthcare software typically struggle. That includes navigating procurement and security review at large providers and payers, structuring early contracts so the economics scale, and building a sales motion that is not dependent on the founder’s personal relationships. A-Squared is candid about what it does not do. It is not a clinical-evidence fund, it is not a therapeutics or device fund, and it is not a generalist consumer health fund. For founders building AI-enabled software to solve real US healthcare administrative and operational problems, it is one of the more focused early-stage partners in the Israeli ecosystem. Expect a partner who will press on the specifics of the business rather than the narrative, who will engage with the actual customer conversations, and who will treat the fund’s job as getting the company to a Series A worth raising rather than getting the deck to a Series A worth pitching.